Flamel maintained by Merrill at neutral

French drug delivery biotech Flamel Technologies Corp. was maintained by Merrill Lynch analyst Hari Sambasivam at a neutral rating ahead of the companies earnings, which are due to be reported July 20. Flamel engages in the development and commercialization of controlled-release therapeutic products based on its proprietary polymer-based technologies. In the U.S., Flamel shares Friday were unchanged at $19.44 on volume of 76,701 shares versus the three-month running average of 253,791.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.